SiBone (NASDAQ:SIBN) Shares Acquired by Legato Capital Management LLC

Legato Capital Management LLC raised its position in SiBone (NASDAQ:SIBN - Free Report) by 58.4% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 99,356 shares of the company's stock after buying an additional 36,649 shares during the quarter. Legato Capital Management LLC owned approximately 0.23% of SiBone worth $1,394,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also modified their holdings of the company. Virtus Fund Advisers LLC acquired a new position in shares of SiBone in the fourth quarter valued at approximately $40,000. GAMMA Investing LLC increased its holdings in shares of SiBone by 20,352.6% in the first quarter. GAMMA Investing LLC now owns 3,886 shares of the company's stock valued at $55,000 after purchasing an additional 3,867 shares during the period. KLP Kapitalforvaltning AS acquired a new position in shares of SiBone in the fourth quarter valued at approximately $97,000. Johnson Investment Counsel Inc. acquired a new position in SiBone during the first quarter worth $148,000. Finally, Proficio Capital Partners LLC acquired a new position in SiBone during the fourth quarter worth $155,000. Institutional investors and hedge funds own 98.11% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on SIBN shares. Truist Financial upped their price objective on SiBone from $20.00 to $22.00 and gave the stock a "buy" rating in a report on Tuesday, May 6th. Needham & Company LLC reiterated a "buy" rating and set a $24.00 target price on shares of SiBone in a research report on Tuesday, May 6th. Finally, Cantor Fitzgerald reiterated an "overweight" rating and set a $25.00 target price on shares of SiBone in a research report on Tuesday, May 6th.

SiBone Trading Down 0.6%

Shares of SiBone stock traded down $0.11 during trading hours on Friday, reaching $17.25. The stock had a trading volume of 208,797 shares, compared to its average volume of 344,467. The firm has a 50 day simple moving average of $18.05 and a two-hundred day simple moving average of $16.56. The firm has a market capitalization of $735.20 million, a price-to-earnings ratio of -26.95 and a beta of 0.93. The company has a current ratio of 8.53, a quick ratio of 7.26 and a debt-to-equity ratio of 0.21. SiBone has a 1 year low of $11.70 and a 1 year high of $20.05.

SiBone (NASDAQ:SIBN - Get Free Report) last posted its earnings results on Monday, May 5th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.24) by $0.09. SiBone had a negative return on equity of 16.00% and a negative net margin of 15.03%. The business had revenue of $47.29 million during the quarter, compared to analyst estimates of $45.13 million. As a group, equities research analysts anticipate that SiBone will post -0.78 earnings per share for the current year.

Insider Activity

In other news, CFO Anshul Maheshwari sold 5,005 shares of SiBone stock in a transaction that occurred on Wednesday, July 2nd. The stock was sold at an average price of $18.34, for a total value of $91,791.70. Following the completion of the transaction, the chief financial officer owned 217,078 shares in the company, valued at approximately $3,981,210.52. This trade represents a 2.25% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jeffrey W. Dunn sold 3,377 shares of SiBone stock in a transaction that occurred on Thursday, June 5th. The stock was sold at an average price of $19.05, for a total value of $64,331.85. Following the completion of the transaction, the director owned 17,354 shares of the company's stock, valued at approximately $330,593.70. The trade was a 16.29% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 101,702 shares of company stock worth $1,866,404 over the last quarter. Corporate insiders own 4.00% of the company's stock.

SiBone Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.